Navigation Links
YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
Date:3/15/2010

About YM BioSciences

YM BioSciences Inc. is a life sciences product development company. The Company is currently developing four late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM); CYT387, a highly selective JAK 1/2 small molecule inhibitor, CYT997, an orally bioavailable, potent, vascular disrupting agent (VDA) and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is importantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries. In more than 9,000 patients reported as having been treated with nimotuzumab worldwide to date, Grade IV incidents of radiation dermatitis and incidents of severe rash have been only rarely observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been equally rare. Nimotuzumab is licensed to YM's majority-owned, Canadian subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. The clinical stage products discovered by Cytopia Ltd (YM Australia since January 2010'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Md. (PRWEB) August 19, 2014 ... liquid chromatography systems, Prominence-i and Nexera-i, adding to ... systems. Combining excellent functionality, an intuitive operating environment, ... and a more efficient workflow for conventional to ... feature innovative, intuitive and intelligent design so users ...
(Date:8/19/2014)... 2014 Research and Markets  has announced the ... Global Strategic Business Report" report to their offering. ... Oxide Fuel Cells (SOFCs) in US$ Thousands. The report provides ... , Europe , Asia-Pacific ... provided for the period 2012 through 2020. Market data and ...
(Date:8/19/2014)... Md. , Aug. 19, 2014 CSSi, ... research industry, recently announced the formation of the company,s ... to announce the addition of Dr. William E. ... - http://photos.prnewswire.com/prnh/20140818/136957 The MCAB, ... a variety of therapeutic areas and set strategic goals ...
(Date:8/19/2014)... August 19, 2014 Sales Horizons, a ... its online sales skills training course to ... , MedTech clinical staff spend the majority of their ... standalone medical center, or physician practice – providing support ... why stop there? Sales Horizons believes clinical staff are ...
Breaking Biology Technology:Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3
... the past few years, the design and manufacturing of ... one of the frontier fields in new material science ... often is accompanied by new discoveries in how they ... dimensions. Understanding this new physics at nanoscopic scale at ...
... Collaboration on Titan Spine,s Endoskeleton(R) ... DURANGO, Colo., Oct. 8 Syndicom, the creator ... TraumaConnect.com,announced today it will be working with Titan ... its surgeons to,efficiently expedite their understanding of, and ...
... 8 CJPS Enterprises, LLC, (http://www.CJPS-Enterprises.com ), ... (http://www.MichiganPipeline.com ) is announcing a new ... for their business, or looking to,invest in ... of the existing resources available on the ...
Cached Biology Technology:A new material could act as a nanofridge for microchips 2Titan Spine Teams Up With Syndicom, Inc. to Utilize Internationally Recognized SpineConnect Collaboration Platform 2The Michigan Life Sciences Pipeline Announces 'The Funding Place(TM)' and Other Resources to Connect Investors and Startups 2
(Date:8/19/2014)... and Network-Level Science, , Imagine if we had the ... was responding to global changes in real time. Such ... multiple decades of information about ecological responses to environmental ... of different ecosystem types. , In fact, this ... Network, which will soon celebrate its 35th anniversary. , ...
(Date:8/19/2014)... leprosy and tuberculosis live side-by-side. Worldwide there are ... with nearly all of them occurring where tuberculosis ... Calmette-Guerin, or BCG, provides only partial protection against ... vaccine is needed to combat both diseases. UCLA-led ... both diseases., In a study published in the ...
(Date:8/19/2014)... MIT chemical engineers have devised a new implantable tissue ... slowly over a few weeks. When applied to bone ... to rapidly form new bone that looks and behaves ... coated scaffold could offer a dramatic improvement over the ... bone from another part of the patient,s body ...
Breaking Biology News(10 mins):This week from AGU: Long-term ecological research, predicting cholera outbreaks 2New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Engineering new bone growth 2Engineering new bone growth 3
... - The growth in China,s carbon dioxide (CO2) emissions ... stabilizing atmospheric greenhouse gases even more difficult, according to ... California, Berkeley, and UC San Diego. Previous estimates, ... Change, say the region that includes China will see ...
... Research Prize and Medal will be awarded to Philip R. ... of Overseers and NJIT President Robert A. Altenkirch on March ... Solar-Terrestrial Research which has led a five-year project to build ... Observatory (BBSO), Big Bear Lake, CA. First light ...
... was not geographically isolated 25 million years ago ... demonstrated by researchers from the Laboratoire des Mcanismes ... Toulouse 3/IRD) and the Palobiodiversit et paloenvironnements laboratory ... results were obtained thanks to analyses of the ...
Cached Biology News:Alarming growth in expected CO2 emissions in China, finds UC analysis 2Alarming growth in expected CO2 emissions in China, finds UC analysis 3NJIT overseers to award NJIT physicist new medal and prize 2A fossilized giant rhino bone questions the isolation of Anatolia, 25 million years ago 2
The LAS-3000 imaging system combines new CCD camera technology with a simplified user interface to provide significantly improved system sensitivity with a wide range of modularities. This system is...
This kit is designed to select cells labeled with biotinylated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
This pump accomodates StemSep ; pump feed columns of the following sizes : 0.3in., 0.5in., 0.6in., and 1.0in.....
... 50 assays. The TUNEL-based assay kit ... control cells for convenient detection of DNA ... The assay offers an one-step labeling of ... is a hallmark of apoptosis in mammalian ...
Biology Products: